Objective. The purpose of this study was to investigate transitional changes in the incidence of glucocorticoid-associated osteonecrosis in SLE patients, with a focus on immunosuppressive agent and glucocorticoid consumption.
Introduction
Multifocal osteonecrosis is a well-known complication in patients who undergo systemic glucocorticoid therapy. This glucocorticoid-associated osteonecrosis is presumed to arise from circulatory impairment to the epiphysis [1] , osteocyte apoptosis and death [2] , although the exact pathogenesis is currently unclear. Among patients with a history of systemic glucocorticoid administration, SLE was reported most frequently [3] . Oinuma et al. [4] reported a 44% incidence of osteonecrosis in adult patients with SLE.
MRI is a non-invasive diagnostic tool that enables osteonecrosis to be detected much earlier and with greater sensitivity and specificity than simple X-ray and bone scintigraphy [5] . Although it is asymptomatic at the time of osteonecrosis development, MRI can visualize the osteonecrosis with low intensity band in the T1 image during the early phase of up to 3 months after glucocorticoids start [6] . Gradually, the necrotic area becomes mechanically vulnerable, and when it collapses, it causes pain. In other words, there is a time lag from development of osteonecrosis to symptomatic onset by collapse of the femoral head. At the time of collapse, MRI shows diffuse bone marrow oedema with low intensity in the T1 image and high intensity in the short tau inversion recovery sequence (or STIR) image [7] . MRI screening of osteonecrosis is important because incidence of osteonecrosis is frequent after high-dose glucocorticoids therapy and surgical treatment is often required [8] . Sakamoto [9] revealed that the incidence of osteonecrosis was highest in the hip (63%), followed by the knee (51%), ankle (16%) and shoulder joints (16%), while the incidence of osteonecrosis in the ankle and shoulder was 0% in a patient without osteonecrosis in the hips or knees. Nakamura et al. [10] observed no new lesions in the first year following initiation of glucocorticoid administration in SLE patients who received low-dose glucocorticoids for more than a decade; delayed osteonecrosis occurred in only one patient, who experienced an SLE recurrence. These results suggest that MRI of bilateral hip and knee joints is a sufficient screening method for osteonecrosis during the first year of glucocorticoid therapy.
Recently, immunosuppressive regimens for renal allografts have improved, resulting in a decreased incidence of osteonecrosis, presumably due to reduced glucocorticoid doses [11, 12] . However, it is unclear whether these improved immunosuppressive regimens would lead to a similar decrease in the incidence of osteonecrosis in patients with autoimmune diseases. The purpose of this study was to clarify temporal trends in the incidence of osteonecrosis in SLE patients, with a focus on immunosuppressant agent and glucocorticoid consumption.
Methods
The research protocol of this retrospective observational cohort study was approved by the Research Ethics Committees of the Graduate School of Medicine, Chiba University Board in compliance with the Helsinki Declaration. The participants were informed by bulletin board.
We retrospectively studied 238 SLE patients who received glucocorticoid therapy from 1986 to 2015. The inclusion criteria were: fulfillment of the ACR 1982 revised criteria for the classification of SLE [13] ; newly diagnosed SLE managed by hospitalization and administration of initial glucocorticoid therapy; and MRI screening of hips and knees during the first year following initial glucocorticoid administration. Eighteen patients who were previously diagnosed with SLE and were hospitalized for recurrence and 35 patients who did not undergo MRI screening were excluded. The remaining 185 patients with 740 joints comprised the study group for subsequent analyses.
Trends in immunosuppressive agent and glucocorticoid consumption were surveyed. Survey items concerned the use of intermittent pulse intravenous CYC therapy, calcineurin inhibitors (ciclosporin or tacrolimus) and glucocorticoid usage (steroid pulse therapy and highest daily glucocorticoid dose per oral dose) that were administered at the time of initial admission. Calcineurin inhibitors were introduced in 2000. As a policy of rheumatologists in our hospital, immunosuppressive drugs have been intentionally prescribed to reduce the amount of steroid use. Therefore, patients were divided into two groups: the past group (198699) and the recent group (200015). Our indication of hospitalization depends on the severity of organ lesions and the treatment strategy for SLE was consistent throughout the study period.
Incidence of osteonecrosis
The diagnosis of osteonecrosis was based on the 2001 revised criteria for classification of osteonecrosis of the femoral head from the Japanese Ministry of Health, Labor and Welfare [14] . Osteonecrosis of the knee was diagnosed in the same manner as the femoral head. The incidence of osteonecrosis and the extent of the necrotic area in the femoral head by using the type classification [14] was compared between the past and recent groups. Type classification is as follows; type A-lesion occupies the medial one-third or less of the weight-bearing portion; type B-lesion occupies the medial two-thirds or less of the weight-bearing portion; type C1-lesion occupies more than the medial two-thirds of the weight-bearing portion but does not extend laterally to the acetabular edge; and type C2-lesion extends laterally to the acetabular edge.
Risk factors for osteonecrosis
Age at initial glucocorticoid therapy, sex, complement (C3, C4, CH50) and anti-DNA antibody before initial glucocorticoid therapy, the organ lesion at hospitalization (because each patient had a variety of symptoms, we counted them in duplicate) were compared between the past and recent groups. The highest daily glucocorticoid dose (mg/day) and the highest daily glucocorticoid dose per weight (mg/day/kg), and cumulative dose at 3 months (mg) were compared. Glucocorticoid doses were converted into equivalent prednisone doses based upon the https://academic.oup.com/rheumatology method of Felson and Anderson [15] . Furthermore, anticoagulants and antilipidemic drugs were compared during the first 3 months after glucocorticoid therapy.
Statistical analysis JMP Pro 12.0 (SAS, Cary, NC, USA) was used for contingency table analysis with Pearson's Chi-square tests, and comparisons of unpaired groups with the MannWhitney U test. Multivariate logistic regression analysis was calculated for osteonecrosis development as a dependent variable with treatment methods (intravenous CYC therapy, calcineurin inhibitors, steroid pulse and highest daily glucocorticoid dose) as independent variables. P < 0.05 was considered significant.
Results
Trends in immunosuppressive agent and glucocorticoid consumption are shown in Fig. 1 . Characteristics of patients in the past and recent periods were similar in terms of clinical manifestations and disease activity (Table 1) .
Glucocorticoid doses were significantly lower in the recent group than in the past group (highest daily glucocorticoid dose, 45.7 vs 59.0 mg/day; highest daily glucocorticoid dose per weight, 0.88 vs 1.16 mg/day/kg; and cumulative dose at 3 months, 3118 vs 3985 mg).
The highest daily glucocorticoid dose was significantly lower in the recent period than in the past period (45.7 vs 59.0 mg/day, respectively). The highest daily glucocorticoid dose per weight was also significantly lower in the recent period than in the past period (0.88 vs 1.16 mg/ day/kg, respectively).
The incidence of osteonecrosis was significantly lower in the recent period than in the past period (26.3 vs 41.0%, respectively). With respect to osteonecrosis of the knee joint, the incidence was also significantly lower in the recent period than in the past period (25.4 vs 46.6%, respectively). In hip joints, the incidence of osteonecrosis also tended to be lower in the recent period than in the past period (27.1 vs 35.3%, respectively), without statistical significance. The extent of osteonecrosis of the femoral head showed almost similar distribution of the type classification between two groups.
In the past period, glucocorticoid doses were significantly lower in the group without osteonecrosis than in the group with osteonecrosis (highest daily glucocorticoid dose, 57.2 vs 60.9 mg/day, P = 0.006; highest daily glucocorticoid dose per weight, 1.12 vs 1.22 mg/day/kg, P = 0.001), except cumulative dose at 3 months (3928 vs 4031 mg, P = 0.90). However, in the recent period, glucocorticoid doses were similar between the groups without osteonecrosis and with osteonecrosis (highest daily glucocorticoid dose, 47.5 vs 46.9 mg/day, P = 0.65; highest daily glucocorticoid dose per weight, 0.90 vs 0.91 mg/ day/kg, P = 0.93; and cumulative dose at 3 months, 3081 vs 3186 mg, P = 0.21). The use of anticoagulants was not Logistic regression analysis showed that only highest daily glucocorticoid dose was significantly related to occurrence of osteonecrosis (odds ratio: 1.05/1 mg/day increase, 95% CI: 1.01, 1.07, P = 0.007).
Discussion
To our knowledge, this is first study to investigate transitional changes in the incidence of glucocorticoid-induced osteonecrosis in SLE patients focusing on immunosuppressant drugs and glucocorticoids. Glucocorticoid administration and the incidence of osteonecrosis were significantly decreased following the introduction of calcineurin inhibitors (tacrolimus and CSA) in 2000. We suggest that these improved immunosuppressive regimens have reduced the demand for corticosteroids, and we hypothesize that reduction of corticosteroid doses will further decrease the incidence of osteonecrosis. At the same time, rheumatologists should still pay attention to the fact that the incidence of osteonecrosis remains high, at about 26%, after initial corticosteroid therapy.
Many studies have examined the relationship between glucocorticoid administration and osteonecrosis in renal allografts [11, 12] , but the association between glucocorticoid dosage itself and osteonecrosis remains controversial. Sakai et al. [11] reported that 16% of renal allograft patients treated with ciclosporin developed osteonecrosis, whereas none of the patients who received tacrolimus had osteonecrosis, suggesting that tacrolimus might be associated with a lower incidence of osteonecrosis compared with ciclosporin. Takao et al. [12] observed a lower incidence of osteonecrosis of the hip and knee (4.7%) in renal allograft recipients treated with improved immunosuppressive regimens (ciclosporin or tacrolimus), which reduced cumulative glucocorticoid doses. However, no reports have been published about trends in the association between immunosuppressive agents/glucocorticoids and osteonecrosis in autoimmune disease.
New treatment strategies for SLE are currently being evaluated. Based on evidence, MMF is recommended as a first-line drug for both remission induction and maintenance therapy of active LN by ACR guidelines for screening, case definition, treatment and management of LN [16] . The multi-target therapy with MMF, steroids and tacrolimus has been proposed for active LN [17] . As adjunctive treatments, HCQ is recommended for all SLE patients with nephritis, unless there is a contra-indication [18] . MMF suppresses lymphocyte proliferation in vivo, and HCQ inhibits IFN-a production [19] . These new therapies might further reduce the dependence of SLE patients on glucocorticoids, thereby decreasing the risk of osteonecrosis. This study had several limitations. First, due to its retrospective nature, the immunosuppressive regimens used reflected physician preference and were not uniform. Calcineurin inhibitor use increased after 2000; to address this, patients were divided into two cohorts depending on whether they were treated before 2000 (past) or from 2000 onwards (recent). Second, we documented the extent of necrotic areas, but could not follow up the patients. Improved immunosuppressive regimens would be expected to reduce the collapse of osteonecrosis and long-term outcome. Third, we only registered inpatients, but not outpatients, to limit the analysis to SLE patients who received high-dose glucocorticoid therapy. The treatment strategy of SLE in our hospital has not changed during the research period. Slight SLE patients, with a skin lesion but without a serious organ lesion or a joint lesion, weres treated in an outpatient clinic. Such patients were not routinely screened with MRI because the amount of glucocorticoid was small and the risk of osteonecrosis deemed to be low. Thus, the precise occurrence of osteonecrosis could not be ascertained. However, the characteristics of the two cohorts of the past and the recent groups were similar in terms of clinical manifestations and disease activity; therefore, we believe that it does not have a big influence on this research. Fourth, the pathogenesis of osteonecrosis itself has not yet been elucidated. Some patients do not develop osteonecrosis even with same regimen of high-dose glucocorticoid therapy [10] , although generally the incidence of osteonecrosis gradually increases with increasing glucocorticoid dose and gradually decreases with decreasing glucocorticoid dose [3] . Therefore, the association between glucocorticoid dose and osteonecrosis may be a stochastic and not a deterministic effect. Gene polymorphism may play a role in steroid sensitivity [20] . The prophylaxis for steroid-associated osteonecrosis has not yet been established, and further study of this condition is needed.
In conclusion, the incidence of glucocorticoid-associated osteonecrosis in SLE patients has decreased in association with decreased glucocorticoid administration following the introduction of immunosuppressant agents. Hydroxychloroquine-induced dark butterfly rash in a rheumatoid arthritis patient A 57-year-old female presented to us with a dark-pigmented skin rash on the face as well as mild arthralgias and arthritis on second and third MCP and wrists. She reported no other medical conditions. One year ago, the patient was started on HCQ 200 mg twice daily, MTX 12, 5 mg and folic acid 5 mg once a week, after the diagnosis of seronegative RA was established by a private doctor. Within 8 months of treatment, with moderate clinical response, she developed the skin rash depicted in Fig. 1 , after prolonged exposure to sunlight during gardening. At the beginning, the skin had an erythematous colour, but gradually turned into a dark-pigmented rash.
HCQ is an antimalarial drug often used in RA and Lupus [1] patients for treating mild arthralgias. Side effects of HCQ such as photosensitive rashes or skin pigmentation are not uncommon [2] , but the distribution of this particular skin manifestation, resembling Lupus butterfly rash, is very unusual.
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